Disposition and safety of omapatrilat in subjects with renal impairment

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 3, 2000, Pages 261-269

  Sica, Domenic A ^a,b   Liao, Wei chi ^a,b   Gehr, Todd W B ^a,b   Khan, Sanaulla ^a,b   Jemal, Mohammad ^a,b   Delaney, Carol L ^a,b   Ferreira, Irene M ^a,b   Malhotra, Bimal K ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC S OXIDE OMAPATRILAT; DIPEPTIDYL CARBOXYPEPTIDASE; DRUG METABOLITE; OMAPATRILAT; PHENYLMERCAPTOPROPIONIC ACID; PROTEINASE; S METHYLOMAPATRILAT; S METHYLPHENYL MERCAPTOPROPIONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG STRUCTURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIDINES; RENAL DIALYSIS; THIAZEPINES;

EID: 0033830022     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.109033     Document Type: Article

References (23)

1. Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
2. Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme
3. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase
4. Dose-related anti-hypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, in models of normal and low renin hypertension
5. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
6. Effects of omapatrilat in low, normal, and high renin experimental hypertension
7. Antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril
8. Omapatrilat, a novel cardiovascular agent, improves hemodynamics in patients with heart failure
9. The effects of omapatrilat, a combined inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on arterial function in chronic heart failure
10. USRDS 1999 Annual Data Report Chapter II. Incidence and Prevalence of ESRD. Ann Arbor, Michigan: Coordinating Center of the USRDS, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), in conjunction with the Health Care Financing Administration (HCFA), 1999
11. End-stage renal disease in African-American and white men: 16-year MRFIT findings
12. Omapatrilat increases key vascular/renal markers regardless of renal function
13. High performance liquid chromatography/ionspray mass spectrometry of N-ethylmaleimide and acrylic acid ester derivatives for bioanalysis of thiol compounds
14. Quantitative determination of BMS186716, a thiol compound, in dog plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct
15. Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases
16. Steady-state PK of omapatrilat in healthy subjects
17. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension
18. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension
19. Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hypertension
20. Human kidney 'enkephalinase,' a neutral metalloendopeptidase that cleaves active peptides
21. Role of kinins in the cardioprotective effect of preconditioning: Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats
22. The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: A pilot study
23. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor